

# Clinical Schizophrenia & Related Psychoses

Volume 3 • April 2009–January 2010

No. 1 (April 2009) ..... Pages 1-70  
No. 2 (July 2009) ..... Pages 71-120  
No. 3 (October 2009) ..... Pages 121-170  
No. 4 (January 2010) ..... Pages 171-236

## Key Word Index

### - A -

#### Adherence

Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

#### Aggression

The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

#### Agitation

The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

#### Akathisia

A brief overview of iatrogenic akathisia [Advokat] 3(4):226-236-cr

#### Alcohol

A descriptive study of nicotine, alcohol, and cannabis use in urban, socially disadvantaged, predominantly African-American patients with first-episode nonaffective psychosis [Stewart et al.] 3(4):217-225-oc

#### Anticonvulsants

The importance of screening for osteoporosis in mental health settings [Miller] 3(3):155-160-cr

#### Antipsychotic

Preventive interventions for schizophrenia: a case report [Tahir] 3(2):117-120-crep

The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

Schizophrenia: 1979–2009 [Seeman] 3(3):161-167-cc

The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

A pilot study to determine a prolactin threshold that identifies improved sexual functioning when switching from a prolactin-elevating to a prolactin-neutral antipsychotic [Byerly and Nakonezny] 3(4):209-216-oc

#### Assessment

Assessment of substance use and substance-use disorders in schizophrenia [Bennett] 3(1):50-63-cr

### - B -

#### Brain

A review of diffusion tensor imaging in schizophrenia [Rowland et al.] 3(3):142-154-cr

### - C -

#### Cannabis

A descriptive study of nicotine, alcohol, and cannabis use in urban, socially disadvantaged, predominantly African-American patients with first-episode nonaffective psychosis [Stewart et al.] 3(4):217-225-oc

#### Clozapine

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

## Key To Abbreviations

Case Report – crep  
Clinical Commentary – cc  
Clinical News – cn  
Comprehensive Review – cr  
Consumer Perspectives – cp

CS eInterview – int  
Current Clinical Trial – cct  
Meeting Highlights – mh  
Original Contribution – oc

## Key Word Index

Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

### Cognition

Depressive symptomatology and attributional style in patients with schizophrenia [Sanjuan et al.] 3(1):31-38-oc

Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

### Cognitive Behavioral Therapy (CBT)

Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

### Compliance

Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

### Computed Tomography

An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc

### Connectivity

A review of diffusion tensor imaging in schizophrenia [Rowland et al.] 3(3):142-154-cr

**-D-**

### Diffusion Tensor Imaging

A review of diffusion tensor imaging in schizophrenia [Rowland et al.] 3(3):142-154-cr

**-E-**

### Endocrine

A pilot study to determine a prolactin threshold that identifies improved sexual functioning when switching from a prolactin-elevating to a prolactin-neutral antipsychotic [Byerly and Nakonezny] 3(4):209-216-oc

**-F-**

### Factor

The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

### Family Involvement

Involving families in the care of persons with schizophrenia and other serious mental illnesses: history, evidence, and recommendations [Drapalski et al.] 3(1):39-49-cr

### Family Services

Involving families in the care of persons with schizophrenia and other serious mental illnesses: history, evidence, and recommendations [Drapalski et al.] 3(1):39-49-cr

### First-Episode Psychosis

An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc

A descriptive study of nicotine, alcohol, and cannabis use in urban, socially disadvantaged, predominantly African-American patients with first-episode nonaffective psychosis [Stewart et al.] 3(4):217-225-oc

### Fluphenazine Decanoate

Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia [Shafti] 3(2):97-102-oc

**-H-**

### History

Schizophrenia: 1979–2009 [Seeman] 3(3):161-167-cc

**-I-**

### Insight

Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

**-M-**

### Management

Schizophrenia: 1979–2009 [Seeman] 3(3):161-167-cc

### Marijuana

A descriptive study of nicotine, alcohol, and cannabis use in urban, socially disadvantaged, predominantly African-American patients with first-episode nonaffective psychosis [Stewart et al.] 3(4):217-225-oc

### Measures

Assessment of substance use and substance-use disorders in schizophrenia [Bennett] 3(1):50-63-cr

### Mental Health

The importance of screening for osteoporosis in mental health settings [Miller] 3(3):155-160-cr

### Metabolic Side Effects

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiasen et al.] 3(2):87-96-oc

### Molindone

The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

### Morbidity

Schizophrenia: 1979–2009 [Seeman] 3(3):161-167-cc

### Mortality

Schizophrenia: 1979–2009 [Seeman] 3(3):161-167-cc

**-N-**

### Neuroendocrine

A pilot study to determine a prolactin threshold that identifies improved sexual functioning when switching from a prolactin-elevating to a prolactin-neutral antipsychotic [Byerly and Nakonezny] 3(4):209-216-oc

### Nicotine

A descriptive study of nicotine, alcohol, and cannabis use in urban, socially disadvantaged, predominantly African-American patients with first-episode nonaffective psychosis [Stewart et al.] 3(4):217-225-oc

**-O-**

### Olanzapine

Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia [Shafti] 3(2):97-102-oc

The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

### Osteoporosis

The importance of screening for osteoporosis in mental health settings [Miller] 3(3):155-160-cr

## -P-

### PANSS

The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

### Poorly Responsive Schizophrenia

Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia [Shafti] 3(2):97-102-oc

### Positive and Negative Syndrome Scale

The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

### Principal Component Analysis

The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

### Psychopharmacology

A brief overview of iatrogenic akathisia [Advokat] 3(4):226-236-cr

### Psychosis

Preventive interventions for schizophrenia: a case report [Tahir] 3(2):117-120-crep

Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

## -R-

### Randomized Controlled Trial (RCT)

Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

### Risperidone

The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

## -S-

### Schizophrenia

An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc

Depressive symptomatology and attributional style in patients with schizophrenia [Sanjuan et al.] 3(1):31-38-oc

Involving families in the care of persons with schizophrenia and other serious mental illnesses: history, evidence, and recommendations [Drapalski et al.] 3(1):39-49-cr

Assessment of substance use and substance-use disorders in schizophrenia [Bennett] 3(1):50-63-cr

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiasen et al.] 3(2):87-96-oc

The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

Preventive interventions for schizophrenia: a case report [Tahir] 3(2):117-120-crep

Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

A review of diffusion tensor imaging in schizophrenia [Rowland et al.] 3(3):142-154-cr

Schizophrenia: 1979–2009 [Seeman] 3(3):161-167-cc

The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

A descriptive study of nicotine, alcohol, and cannabis use in urban, socially disadvantaged, predominantly African-American patients with first-episode nonaffective psychosis [Stewart et al.] 3(4):217-225-oc

### Serious Mental Illness

Involving families in the care of persons with schizophrenia and other serious mental illnesses: history, evidence, and recommendations [Drapalski et al.] 3(1):39-49-cr

### Side Effect(s)

A pilot study to determine a prolactin threshold that identifies improved sexual functioning when switching from a prolactin-elevating to a prolactin-neutral antipsychotic [Byerly and Nakonezny] 3(4):209-216-oc

A brief overview of iatrogenic akathisia [Advokat] 3(4):226-236-cr

### Skills Training

The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

### Social Cognition

Depressive symptomatology and attributional style in patients with schizophrenia [Sanjuan et al.] 3(1):31-38-oc

### Substance Abuse

A descriptive study of nicotine, alcohol, and cannabis use in urban, socially disadvantaged, predominantly African-American patients with first-episode nonaffective psychosis [Stewart et al.] 3(4):217-225-oc

### Substance Use

Assessment of substance use and substance-use disorders in schizophrenia [Bennett] 3(1):50-63-cr

### Substance-Use Disorders

Assessment of substance use and substance-use disorders in schizophrenia [Bennett] 3(1):50-63-cr

## -T-

### Tobacco

A descriptive study of nicotine, alcohol, and cannabis use

## Author Index

in urban, socially disadvantaged, predominantly African-American patients with first-episode nonaffective psychosis [Stewart et al.] 3(4):217-225-oc

### Treatment Adherence

Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

### -V-

### Vocational Rehabilitation

The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

### -W-

### White Matter

A review of diffusion tensor imaging in schizophrenia [Rowland et al.] 3(3):142-154-cr

### Work Skills

The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

## Author Index

### -A-

#### Advokat, C.

A brief overview of iatrogenic akathisia [Advokat] 3(4):226-236-cr

#### Aguirre, F.

The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

#### Alcantara, F.

The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

### -B-

#### Beebe, L.H.

Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

#### Bennett, M.E.

Assessment of substance use and substance-use disorders in schizophrenia [Bennett] 3(1):50-63-cr

#### Bodnar, M.

Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

#### Buchy, L.

Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

#### Buckley, P.F.

Updates on long-acting injectable antipsychotics 3(1):15-cn

Update on putative cognitive-enhancing drugs 3(1):15-cn

Novel approach to antipsychotic-induced weight gain shows benefits in early clinical trials 3(1):15-cn

Phosphodiesterase inhibitors and schizophrenia treatment 3(1):16-cn

Continued concern about risks of sudden death in patients receiving antipsychotic medications 3(1):16-cn

New meta-analysis of SGAs 3(1):16-cn

Perceptual disturbances evident even in first-episode schizophrenia 3(1):16-cn

What's the overlap between schizophrenia and bipolar: Swedish study provides clues 3(1):16-cn

Stigma still the biggest problem 3(1):17-cn

NAMI releases second "state of the states" audit 3(2):77-cn

New antipsychotic approved: iloperidone receives FDA approval 3(2):77-cn

Sertindole receives favorable FDA recommendation 3(2):77-cn

FDA panel considers antipsychotic use in younger patients 3(2):77-cn

FDA approves risperidone long-acting injection as a treatment as both monotherapy and adjunctive therapy for bipolar I disorder 3(2):78-cn

Asenapine continues under FDA review 3(2):78-cn

FDA considers quetiapine for depression and anxiety disorders 3(2):78-cn

New study information on lurasidone 3(2):78-cn

Updates on long-acting injectable olanzapine 3(2):78-cn

Gene identified for schizophrenia risk 3(2):79-cn

Mistreated children more likely to become psychotic 3(2):79-cn

New psychosis journal launched 3(2):79-cn

Updated British clinical guideline for schizophrenia 3(2):79-cn

#### Burk, R.

Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

#### Byerly, M.J.

A pilot study to determine a prolactin threshold that identifies improved sexual functioning when switching from a prolactin-elevating to a prolactin-neutral antipsychotic [Byerly and Nakonezny] 3(4):209-216-oc

### C-

#### Carpenter, W.T.

An interview with William T. Carpenter, Jr., MD 3(3):168-170-int

#### Ciranni, M.

The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

#### Compton, M.T.

An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc

A descriptive study of nicotine, alcohol, and cannabis use in urban, socially disadvantaged, predominantly African-American patients with first-episode nonaffective psychosis [Stewart et al.] 3(4):217-225-oc

**Cornelius, M.D.**

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

**Curtis, J.L.**

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

**-D-**

**David, A.**

Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

**Dessieux, O.**

Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

**Dixon, L.**

Involving families in the care of persons with schizophrenia and other serious mental illnesses: history, evidence, and recommendations [Drapalski et al.] 3(1):39-49-cr

**Drapalski, A.L.**

Involving families in the care of persons with schizophrenia and other serious mental illnesses: history, evidence, and recommendations [Drapalski et al.] 3(1):39-49-cr

**-E-**

**Esterberg, M.L.**

A descriptive study of nicotine, alcohol, and cannabis use in urban, socially disadvantaged, predominantly African-American patients with first-episode nonaffective psychosis [Stewart et al.] 3(4):217-225-oc

**-F-**

**Fedde, J.**

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

**Fenley, G.**

Checking realities: consumer perspectives. Insight [Fenley] 3(1):64-66-cp

**Filmyer, D.M.**

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

**Fraguas, D.**

Depressive symptomatology and attributional style in patients with schizophrenia [Sanjuan et al.] 3(1):31-38-oc

**-G-**

**Gobeil, M-H.**

The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

**Goulding, S.M.**

An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc

A descriptive study of nicotine, alcohol, and cannabis use in urban, socially disadvantaged, predominantly African-American patients with first-episode nonaffective psychosis [Stewart et al.] 3(4):217-225-oc

**Green, N.**

Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

**-H-**

**Hastilow, S.**

Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

**Haworth, E.**

Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

**Hayward, P.**

Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

**Holcomb, H.H.**

A review of diffusion tensor imaging in schizophrenia [Rowland et al.] 3(3):142-154-cr

**-J-**

**Joober, R.**

Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

**Joseph, A.**

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

**Joseph, M.**

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

**Josiassen, R.C.**

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

**-K-**

**Kasco, M.**

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

**Khan, A.**

The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

**Kopelowicz, A.**

The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

**-L-**

**Lefebvre, A-A.**

The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

**Lehoux, C.**

The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

**Leith, J.**

Involving families in the care of persons with schizophrenia and other serious mental illnesses: history, evidence, and recommendations [Drapalski et al.] 3(1):39-49-cr

**Lepage, M.**

Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

**Lieberman, R.P.**

The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

**Lindenmayer, J.P.**

The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

**-M-**

**Magallares, A.**

Depressive symptomatology and attributional style in patients with schizophrenia [Sanjuan et al.] 3(1):31-38-oc

**Malla, A.**

Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

**Maziade, M.**

The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

**McIntyre, K.B.**

Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

**Merchan-Naranjo, J.**

Depressive symptomatology and attributional style in patients with schizophrenia [Sanjuan et al.] 3(1):31-38-oc

**Miller, B.J.**

Highlights from the Twelfth Biennial International Congress on Schizophrenia Research, San Diego, CA, March 28–April 1, 2009 [Trotman and Miller] 3(2):80-86-mh

**Miller, M.J.**

The importance of screening for osteoporosis in mental health settings [Miller] 3(3):155-160-cr

**Mintz, J.**

The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

**Mullins, M.**

An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in

patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc

**-N-**

**Nakonezny, P.A.**

A pilot study to determine a prolactin threshold that identifies improved sexual functioning when switching from a prolactin-elevating to a prolactin-neutral antipsychotic [Byerly and Nakonezny] 3(4):209-216-oc

**Nasrallah, H.A.**

An interview with Henry A. Nasrallah, MD 3(1):67-70-int

**Nathan, S.**

An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc

**-P-**

**Parson, R.L.**

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

**Pringle, M.**

A descriptive study of nicotine, alcohol, and cannabis use in urban, socially disadvantaged, predominantly African-American patients with first-episode nonaffective psychosis [Stewart et al.] 3(4):217-225-oc

**-R-**

**Rabe-Hesketh, S.**

Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

**Resnick, B.**

Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

**Ressler, K.**

An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc

**Rowand, L.M.**

A review of diffusion tensor imaging in schizophrenia [Rowland et al.] 3(3):142-154-cr

**Roy, M-A.**

The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

**-S-**

**Sanjuan, P.**

Depressive symptomatology and attributional style in patients with schizophrenia [Sanjuan et al.] 3(1):31-38-oc

**Seeman, M.V.**

Schizophrenia: 1979–2009 [Seeman] 3(3):161-167-cc

**Shaffer, S.**

Promoting therapeutic alliance in clozapine users: an exploratory

randomized controlled trial [Hayward et al.] 3(3):127-132-oc

**Shafti, S.S.**

Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia [Shafti] 3(2):97-102-oc

**Shaughnessy, R.A.**

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

**Skuban, N.**

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

**Smith, K.**

Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

**Spieker, E.A.**

A review of diffusion tensor imaging in schizophrenia [Rowland et al.] 3(3):142-154-cr

**Stewart, T.**

A descriptive study of nicotine, alcohol, and cannabis use in urban, socially disadvantaged, predominantly African-American patients with first-episode nonaffective psychosis [Stewart et al.] 3(4):217-225-oc

**-T-**

**Tahir, M.S.**

Preventive interventions for schizophrenia: a case report [Tahir] 3(2):117-120-crep

**Tavakoli, A.**

Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

**Tennison, C.**

Motivating persons with schizophrenia spectrum disorders to

exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

**Thompson, N.**

Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

**Trotman, H.D.**

Highlights from the Twelfth Biennial International Congress on Schizophrenia Research, San Diego, CA, March 28–April 1, 2009 [Trotman and Miller] 3(2):80-86-mh

**-V-**

**Velligan, D.**

Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

**Victor, T.**

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

**-W-**

**Wallace, C.J.**

The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

**Weinstein, J.**

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

**Whicker, N.E.**

An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc

**Wykes, T.**

Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc